|
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Clinical research trials and Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia. Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia clinical trial. Human subjects often get the best healthcare possible for their Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia  Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
For Condition: Head and Neck Cancer
Status: Recruiting
Sponsor(s): Dana-Farber/Harvard Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing head and neck cancer in patients who have oralleukoplakia or head and neck dysplasia. PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have oral leukoplakia and/or head and neck dysplasia.
Details: OBJECTIVES: - Determine the response rate, in terms of prostaglandin E2 expression, in patients with oral leukoplakia and/or dysplasia treated with celecoxib. - Determine the change in other biomarkers including COX-2, Ak+, Ki-67, BCL2, BAX, VEGF, and CD31, in patients treated with this drug. - Determine the efficacy of this drug, in terms of reducing the size of oral leukoplakia lesions and presence of dysplasia, in these patients. - Correlate change in biomarker expression with response of oral leukoplakia lesions and/or dysplasia in patients treated with this drug. - Determine the toxic effects of this drug in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive oral celecoxib twice daily for 3 months. After 3 months, patients undergo a repeat biopsy. Patients with a positive response receive celecoxib for an additional 9 months. Patients are followed every 3-6 months for 1 year. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 30 months.
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Oral leukoplakia on clinical examination AND/OR - More than one prior squamous cell carcinoma (SCC) of the head and neck and dysplasia on biopsy within the past 6 months - Carcinoma in situ or new leukoplakia eligible provided treatment for a prior carcinoma was completed more than 9 months ago PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - At least 12 months Hematopoietic - Platelet count at least 100,000/mm^3 - Absolute neutrophil count greater than 1,500/mm^3 - No bleeding diathesis Hepatic - Bilirubin less than 1.5 times upper limit of normal (ULN) - Transaminases less than 1.5 times ULN - PT/PTT less than 1.5 times ULN - No acute or chronic liver disease Renal - Creatinine less than 1.5 times ULN - Urine protein less than 2+ - No acute or chronic renal insufficiency Cardiovascular - No New York Heart Association class II congestive heart failure - No prior myocardial infarction - No angina - No known coronary artery disease Pulmonary - No advanced chronic obstructive pulmonary disease requiring home oxygen use Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No infection within the past 2 weeks - No concurrent infection - No concurrent tobacco use (e.g., cigarette, cigar, pipe, or chewing tobacco) - At least 1 month since prior use - No active alcohol abuse - No history of gastrointestinal ulcer - No history of anaphylactoid reaction to aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors - No concurrent active malignancy except non-melanoma skin cancer - No contraindication to nasopharyngoscopy and biopsy PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent biologic therapy Chemotherapy - No concurrent chemotherapy Endocrine therapy - More than 3 months since prior absorbed steroids, including inhaled and nasal steroids (3 times a week for at least 2 consecutive weeks) - Prior mometasone allowed Radiotherapy - No concurrent radiotherapy Surgery - Prior surgery for SCC of the head and neck allowed provided patient has been cancer free for at least 9 months Other - More than 3 months since prior full-dose aspirin, COX-2 inhibitors, or NSAIDs (at least 3 times a week for at least 2 weeks) - More than 3 months since prior retinoids or selenium - No concurrent lithium or fluconazole - No concurrent diuretics for congestive heart failure - No concurrent angiotensin-converting enzyme inhibitors - Concurrent aspirin allowed if dosage no greater than 81 mg per day
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LoriWirth, Study Chair, Dana-Farber/Harvard Cancer Center
Massachusetts General Hospital Cancer Center *Recruiting*
Boston, Massachusetts, 02114-2617
United States
Recruiting John Clark 617-726-8748
Brigham and Women's Hospital *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting James Mueller 617-732-5984
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting Lori Wirth 617-632-3090
Additional Information:
Study ID Numbers: CDR0000258562; DFCI-2002-P-00150/2,DFCI-02024
Study Start Date:
Record last reviewed: February 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00052611
Other Head And Neck Cancer Studies:
1. Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer
2. Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
3. Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
4. EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer
5. Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Related Studies:
Other Head and Neck Cancer Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
|
|
|
|
|
|
|
|
